���构特征与受体作用机制 — Background and Details

By Editorial Desk · published 2025-09-11 · last reviewed 2025-10-14 · Topic

GLP-1 receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-10-14. Numbers and descriptions here follow the published literature rather than marketing material.

结构特征与受体作用机制

皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

Background and Drug Class

Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.

Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.

Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.

Semaglutide at a glance

Mechanism and Pharmacological Class

Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.

Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.

Related pages on this site

• Robust digest
• Material trends
• Verified report
• Practical handbook
• Automated review
• Material trends
• Clear trends
• Smart digest

Background and Mechanism of Action

Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.

Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.

Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.

Semaglutide Structure and Receptor Mechanism

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.

Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.

Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.

Background and Molecular Design

Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.

The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.

Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.

Reference notes

=== 22 December === United States National Security Council spokesperson John Kirby estimated that the Wagner Group deployed 40,000 mercenaries of recruited convicts and 10,000 mercenaries. The North Korean Foreign ministry denied US claims that it was supplying "infantry rockets and missiles into Russia". Speaking to reporters, President Putin referred to the invasion of Ukraine as a "war" and also said that the U.S. Patriot system is "old and does not work as well as the Russian S-300 missile system". Critics stated that referring to the conflict as a "war" is considered a crime under a censorship law signed in March 2022, with a penalty of up to 15 years in prison, and called for the prosecution of Putin. Ukrainian game developer Volodymyr Yezhov was killed defending Bakhmut

=== Precursor to other peroxide compounds === Hydrogen peroxide is a weak acid, forming hydroperoxide or peroxide salts with many metals. It also converts metal oxides into the corresponding peroxides. For example, upon treatment with hydrogen peroxide, chromic acid (CrO3 and H2SO4) forms a blue peroxide CrO(O2)2.

== Further reading == Agulhon, Maurice. The Republican Experiment, 1848–1852 (The Cambridge History of Modern France) (1983) excerpt and text search Amann, Peter H. "Writings on the Second French Republic." Journal of Modern History 34.4 (1962): 409–429. Clark, Christopher (2023). Revolutionary Spring: Fighting for a New World 1848–1849. Penguin Random House. Furet, François. Revolutionary France 1770–1880 (1995), pp 385–437. survey of political history by leading scholar Guyver, Christopher, The Second French Republic 1848–1852: A Political Reinterpretation, New York: Palgrave, 2016 Price, Roger, ed. Revolution and reaction: 1848 and the Second French Republic (Taylor & Francis, 1975). Price, Roger. The French Second Republic: A Social History (Cornell UP, 1972).

=== Post-embryonic retention === In most vertebrates, the notochord develops into secondary structures. In other chordates, the notochord is retained as an essential anatomical structure. The evolution of the notochord within the phylum Chordata is considered in detail by Holland and Somorjai (2020). Vertebrates now have spines so they do not need a notochord. The following organisms retain a post-embryonic notochord:

Sources: en.wikipedia.org

Notes from published material

=== Scaffold === Scaffolds are used to display the heterologous protein on the bacterial cell surface. There are various scaffolds which have been used such as outer membrane proteins, fimbriae/flagella proteins and CPX (circularly permuted OmpX). The CPX scaffold allows peptide fusion at both termini of the scaffold. OMPs are common scaffolds for bacterial display. Proteins can also be displayed on the bacterial cell surface through the use of autotransporters. Autotransporters form part of the type V secretion system. They usually have three domains: leader sequence at the N-terminal; central passenger domain; autotransporter domain at the C-terminal. The heterologous protein is inserted at the passenger domain. Another method of heterologous protein fusion is fusion with fimbriae/flagella, which are filamentous protrusions on the cell surface. There are many fimbriae on mainly Gram-negative bacteria, so displaying proteins on fimbriae is advantageous over some other surface proteins which are less numerous. A disadvantage of using fimbriae is that there is a relatively small insert size limit of 10-30 amino acids.

== External links == IUPAC, Compendium of Chemical Terminology, 5th ed. (the "Gold Book") (2025). Online version: (2006–) "nitrile". doi:10.1351/goldbook.N04151 IUPAC, Compendium of Chemical Terminology, 5th ed. (the "Gold Book") (2025). Online version: (2006–) "cyanide". doi:10.1351/goldbook.C01486

Triglycerides stored in adipose tissue and in other tissues, such as muscle and liver, release fatty acids and glycerol in a process known as lipolysis. Fatty acids are slower than glucose to convert into acetyl-CoA, as first it has to go through beta oxidation. It takes about 10 minutes for fatty acids to sufficiently produce ATP. Fatty acids are the primary fuel source at rest and in low to moderate intensity exercise. Though slower than glucose, its yield is much higher. One molecule of glucose produces through aerobic glycolysis a net of 30-32 ATP; whereas a fatty acid can produce through beta oxidation a net of approximately 100 ATP depending on the type of fatty acid. For example, palmitic acid can produce a net of 106 ATP.

Sources: en.wikipedia.org

Further detail

The country had a 2019 Forest Landscape Integrity Index mean score of 5.95/10, ranking it 90th globally out of 172 countries. Some 3,700 plant species have been identified in the country, from which to date 23 have been declared natural monuments, 74 extinct, 39 endangered, 171 vulnerable, and 1,253 rare. The fauna of Romania consists of 33,792 species of animals, 33,085 invertebrate and 707 vertebrate, with almost 400 unique species of mammals, birds, reptiles, and amphibians, including about 50% of Europe's (excluding Russia) brown bears and 20% of its wolves. Romania is often seen by most as having the shape resembling one of a goldfish.

Classic maple syrup urine disease Intermediate maple syrup urine disease Intermittent maple syrup urine disease Thiamine-responsive maple syrup urine disease E3-deficient maple syrup urine disease These types can be classified based on time of onset, severity of symptoms, and level of BCKAD complex enzyme activity. Generally, the majority of patients will be classified into one of these five categories but some patients affected by maple syrup urine disease do not fit the criteria for the listed sub-divisions and may be categorized into unclassified maple syrup urine disease.

The most common form of body modification related to the penis is circumcision: removal of part or all of the foreskin, and sometimes the frenulum. It is most commonly performed as an elective procedure for prophylactic, cultural, or religious reasons. Infant circumcision can employ modern devices such as the Gomco clamp, Plastibell, and Mogen clamp. The ethics of circumcision in children is a source of controversy. Among the world's major medical organizations, there is a consensus that circumcision reduces heterosexual HIV infection rates in high-risk populations during penile-vaginal sex. There are differing perspectives on the prophylactic efficacy and cost effectiveness of circumcision in developed nations. Circumcision plays a significant role in many of the world's cultures. When performed for religious reasons, it is most common among both Jews and Muslims, among whom it is near-universal.

=== Web services for cheminformatics === CRDD developed an open source platform which allows users to predict inhibitors against novel M. Tuberculosis drug targets and other important properties of drug molecules like ADMET. Following are list of few servers.

Sources: en.wikipedia.org

Frequently asked questions